WASHINGTON -A long-shot measure introduced in Congress to overturn rules limiting government payments for popular anemia drugs signals drug makers and doctors are lobbying harder than ever.Rep. Anna Eshoo, D-Calif., introduced a “resolution of disapproval” late Thursday that would reverse a recent Medicare policy limiting payments for Amgen Inc. (nasdaq: AMGN - news - people )'s Aranesp and Johnson and Johnson (nyse: JNJ - news - people )'s Procrit. Doctors use the drugs to raise the red blood cell levels of cancer patients suffering from anemia.
